| Start: | Feb 3, 2021 - 2:00 pm |
| End: | Feb 3, 2021 - 5:15 pm |
| Venue: | Online event |
| Event website: | https://smart4fabry.cientifis.com/ |
Dear ETPN members, dear colleagues, we are glad to invite you to actively participate in the final online workshop of the Smart4Fabry project to be held on Wednesday, February 3, 2021.
Description of Smart4Fabry
Rare diseases, like Fabry disease, mean a major health problem for a significant number of people in total, but affecting small number of patients for each individual disease.Smart4Fabry is a project conceived and created to obtain a new nanoformulation of GLA, that will improve the efficacy and toleration compared to the actual treatment with non-formulated GLA. The final benefit will be seen as considerable reduction on the Fabry disease treatment cost and a substantial improvement in the life-quality of Fabry disease patients.
Join the Smart4Fabry Final Workshop to learn from expert speakers how, why and for what the solution proposed by Smart4Fabry was conceived, a sign of cooperation at European level to boost nanomedicine development and translation to clinical stages. More information about the workshop can be found hereafter.
How to attend the workshop?
- Registration for the Smart4Fabry workshop is free-of-charge.
- REGISTRATION FORM: You may register for it by clicking on this link and fill the online form.
Program of the final workshop
You may download a pdf version of the program of the Smart4Fabry workshop by clicking on this link.
Facilitator: Nathaly Segovia (CIBER/ICMAB-CSIC). Smart4Fabry project manager.
14:00 – 14:15 Introduction to the clinical problem: Lysosomal Storage Disorders (LSDs)-Fabry: Guillem Pintos Morell (Vall d’Hebron Research Institute).
14:15 – 14:25 Smart4Fabry project: A European joint effort to use nanotechnology in Enzymatic Replacement Therapy development: Nora Ventosa (CIBER/ICMAB-CSIC). Coordinator of the project.
14:25 – 14:45 Optimizing the nanoformulation: a long trip from lab to reality
- • Formulation CQA. Elisabet González (CIBER/ICMAB-CSIC).
- • Targeting peptides. Miriam Royo (CIBER/IQAC-CSIC).
14:45 – 15:25 Does it look nice? Advanced approaches to nanodrugs characterization
- • Technion- Israel Institute of Technology.
- • Characterization of the nanoformulation structure and multi-lamellarity by SAXS. Jan Skov Pedersen (Aarhus University).
15:25 – 15:35 Production Optimization and Scale up-How to not get lost in translation: Alba Córdoba (Nanomol Technologies).
15:35 – 15:45 Making nanomedicines safe: Safety by design: Andreas Falk (BioNanoNet Forschungsgesellschaft mbH (BNN)).
15:45 – 16:05 Break
16:05 – 16:15 The right vehicle, but what about the passenger? – GLA development: José Luis Corchero (CIBER/UAB) & Andreu Soldevila (Leanbiopro).
16:15 – 16:35 Is it working properly: In vitro and in vivo evaluation
- • In vitro and in vivo efficacy of GLA nanoliposomes. Ibane Abasolo (CIBER/ Vall d’Hebron Research Institute).
- • Nonclinical safety evaluation. Hazel Clay (Covance).
16:35 – 16:45 Barriers to be crossed: Challenges on evaluating BBB crossing: Thomas Birngruber (Joanneum Research).
16:45 – 17:15 Round table. Making the most of our results: Open innovation, exploitation and business development: Ángel del Pozo (Biokeralty), Andreu Soldevila (Leanbiopro), Santi Sala (Nanomol Technologies) – Andreas Falk (BioNanoNet Forschungsgesellschaft mbH (BNN)).
